Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AD 4

Drug Profile

AD 4

Alternative Names: L-2-Acetamido-3-mercaptopropionamide; N-Acetylcysteinamide; N-Acetylcysteine amide; AD-4; NACA

Latest Information Update: 24 Jan 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hebrew University of Jerusalem
  • Developer Eucalyptus Ltd; Yissum Research Development Company
  • Class Eye disorder therapies; Neuroprotectants; Small molecules; Sulfhydryl compounds
  • Mechanism of Action Antioxidants; Chelating agents; Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Neurodegenerative disorders

Most Recent Events

  • 09 Jan 2008 Preclinical trials in Neurodegenerative disorders in USA (PO)
  • 09 Jan 2008 AD 4 exclusively licensed to Eucalyptus Ltd. worldwide for the treatment of Neurodegenerative disorders
  • 24 Apr 2007 No development reported - Preclinical for Neuroprotection in Israel (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top